Novavax COVID-19 vaccine (recombinant spike protein nanoparticle with Matrix-M adjuvant)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Novavax COVID-19 vaccine (recombinant spike protein nanoparticle with Matrix-M adjuvant), covering 2025-04-01 to 2025-04-01. Get the full timeline:
Most recent: Clinical Trial Update: Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older [Phase 1, Phase 2]